OMEO: Homoeopathic Association in Aortic Valve Surgery

Sponsor
BOIRON (Industry)
Overall Status
Completed
CT.gov ID
NCT00774293
Collaborator
Hospices Civils de Lyon (Other)
92
1
2
35
2.6

Study Details

Study Description

Brief Summary

Randomized, parallel group, placebo controlled study to assess the effect of an homoeopathic association of Arnica 5 CH et Bryonia 9 CH during aortic valve surgery with extra corporeal circulation, to alleviate inflammation, haemorrhage, myocardial ischemia and pain. This is a pilot study; a confirmative study will be set up if this study is positive.

The study treatment will start the day before surgery, and will comprise 5 granules of each homoeopathic medication, Arnica 5 CH and Bryonia 9 CH, or their matching placebo TID during 5 days, in addition to all routine treatments.) Two groups of 45 patients will be included. Patients have to be over 18 years, to undergo aortic valve surgery only, have no known allergy to one of the study drugs, sign a consent form, and must not have received anti inflammatory drug in the 3 days before surgery. The primary criteria include the amount of drained liquid from the chest, and the CRP evolution from baseline to the 7th postoperative day. Secondary criteria address inflammation, haemorrhage, ischaemia, and pain. A follow-up phone call is given to the patients 30 days after their surgery.

Condition or Disease Intervention/Treatment Phase
  • Drug: placebo
  • Drug: Arnica and Bryonia
Phase 4

Study Design

Study Type:
Interventional
Actual Enrollment :
92 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Preliminary Study of a Homoeopathic Association in Patients Undergoing Aortic Valve Surgery.
Study Start Date :
Sep 1, 2004
Actual Primary Completion Date :
Jun 1, 2007
Actual Study Completion Date :
Aug 1, 2007

Arms and Interventions

Arm Intervention/Treatment
Experimental: 1

Arnica 5CH and Bryonia 9CH (homeopathic drugs)

Drug: Arnica and Bryonia
Arnica 5CH granules, 5 per day plus Bryonia 5CH Granules, 5 per day for 5 days

Placebo Comparator: 2

placebo Arnica 5CH and Bryonia 9CH

Drug: placebo
5 placebo granules for Arnica 5 CH and 5 placebo granules for Bryonia 5 CH

Outcome Measures

Primary Outcome Measures

  1. Amount of drained liquid from the mediastinum or the pleura [At drain removal]

  2. plasma C reactive protein (CRP) at anaesthesia induction, plasma C reactive protein (CRP) [Day 2 and Day 7]

Secondary Outcome Measures

  1. Evolution of body temperature from before surgery to day 2 after surgery. [Day 2]

  2. Time from the end of extra corporeal circulation to closure of the thorax, [Closure of thorax]

  3. Amount of transfusions of erythrocytes, platelets, plasma. [Day 7]

  4. Visual analogical scale (VAS) for pain every 6 hours during stay in PACU, and every day afterwards to day 7, [To day 7]

  5. Amount of analgesic drugs, paracetamol and morphine. [Day 7]

  6. EKG before surgery, 24 and 48 hours after surgery. [48 hours]

  7. Plasma troponin I at induction of anaesthesia, 6, 24 and 48 hours after surgery. [48 hours]

  8. Quality of cicatrisation of sternotomy immediately after surgery, at day 2 and 7 after surgery, on a 4 point scale. [Day 7]

  9. Clinical events: death, new surgery for haemostasis or infection within 2 weeks of surgery, and any event occurring within 30 days after surgery. [30 days]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients over 18 years, undergoing aortic valve surgery with extra corporeal circulation
Exclusion Criteria:
  • acute infectious or inflammatory concomitant disease, known allergy to one of the investigational products, Patients who did not sign the study consent form, patients having received during the 3 days before surgery any corticoids or non steroid anti-inflammatory drug, patient undergoing a surgery other than surgery of the aortic valve in the same intervention, patient undergoing an iterative cardiac surgery, patients under 18 years, patient over 18 years under the protection of the law.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Anaesthesy service, Louis Pradel Hospital Lyon France 69003

Sponsors and Collaborators

  • BOIRON
  • Hospices Civils de Lyon

Investigators

  • Principal Investigator: Jean-Jacques Lehot, MD, Hospices Civils de Lyon, Lyon, France

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00774293
Other Study ID Numbers:
  • Boiron 041052
First Posted:
Oct 17, 2008
Last Update Posted:
Oct 17, 2008
Last Verified:
Oct 1, 2008

Study Results

No Results Posted as of Oct 17, 2008